IRRAS Dirección

Dirección controles de criterios 2/4

El CEO de IRRAS' es Will Martin , nombrado en Jan 2018, tiene una permanencia de 5.83 años. compensación anual total es SEK6.68M, compuesta por 61.2% salario y 38.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.018% de las acciones de la empresa, por valor de SEK32.08K. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 6.8 años, respectivamente.

Información clave

Will Martin

Chief Executive Officer (CEO)

SEK 6.7m

Compensación total

Porcentaje del salario del CEO	61.2%
Permanencia del CEO	5.8yrs
Participación del CEO	0.02%
Permanencia media de la dirección	3.4yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Will Martin en comparación con los beneficios de IRRAS?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	-SEK 196m
Mar 31 2023	n/a	n/a	-SEK 193m
Dec 31 2022	SEK 7m	SEK 4m	-SEK 167m
Sep 30 2022	n/a	n/a	-SEK 164m
Jun 30 2022	n/a	n/a	-SEK 141m
Mar 31 2022	n/a	n/a	-SEK 131m
Dec 31 2021	SEK 3m	SEK 2m	-SEK 136m

Compensación vs. Mercado: La compensación total de Will($USD612.97K) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD235.29K).

Compensación vs. Ingresos: La compensación de Will ha aumentado mientras la empresa no es rentable.

CEO

Will Martin (48 yo)

5.8yrs

Permanencia

SEK 6,679,000

Compensación

Mr. Will Martin has been the Chief Executive Officer at IRRAS AB (publ) since July 01, 2021. He had been the Chief Commercial Officer and a member of the executive management team of IRRAS AB (publ) (IRRAS...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Will Martin	President & CEO	5.8yrs	SEK 6.68m	0.018% SEK 32.1k
Kleanthis Xanthopoulos	Executive Director	2.3yrs	SEK 530.00k	1.15% SEK 2.1m
Griffen Stapp	Interim Chief Financial Officer	2.3yrs	sin datos	0.0022% SEK 4.0k
Sten Gustafsson	Director of Investor Relations	2.7yrs	sin datos	sin datos
Kellie Fontes	Vice President of Human Capital	5.8yrs	sin datos	0.083% SEK 151.0k
Niloufa Insanally	Head of Regulatory Affairs	4.2yrs	sin datos	sin datos

3.4yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de IRRAS se considera experimentado (3.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kleanthis Xanthopoulos	Executive Director	8.8yrs	SEK 530.00k	1.15% SEK 2.1m
Marios Fotiadis	Chairman of the Board	11.8yrs	SEK 540.00k	20.2% SEK 36.7m
Anita Tollstadius	Independent Director	6.8yrs	SEK 380.00k	0.010% SEK 18.4k
Christos Panotopoulos	Special Advisor & Member of Clinical Advisory Board	5.4yrs	sin datos	sin datos
Catherine Gilmore-Lawless	Independent Director	4.5yrs	SEK 471.00k	sin datos

6.8yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de IRRAS se considera experimentada (6.8 años de antigüedad promedio).

IRRAS Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Insufficient new directors

Insufficient new directors

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Recent updates

IRRAS AB (publ) Applies for Its Shares to Be Delisted from Nasdaq Stockholm

IR Holding Bidco Inc. Requests Compulsory Buy-Out and IRRAS Applies for Delisting

Insufficient new directors

Legacy Capital Partners S.C.A. I, Spetses Investments Ltd, Bacara Holdings Limited, Lexington Holding Assets Ltd and Panormos Holding Limited completed the acquisition of a 26.6% stake in IRRAS AB (publ) (OM : IRRAS).

IRRAS AB (publ) to Report Q2, 2023 Results on Aug 04, 2023

IRRAS AB (publ) Provides Sales Guidance for the Second Quarter of 2024

IRRAS AB (Publ) Announces Resignation of Eva Nilsagård as a Board Member

Price target increased by 69% to kr5.00

First quarter 2023 earnings released: kr0.07 loss per share (vs kr0.42 loss in 1Q 2022)

Consensus revenue estimates decrease by 25%

Full year 2022 earnings released: kr0.52 loss per share (vs kr1.89 loss in FY 2021)

IRRAS AB (publ) Announces That the Publication of the First Comparative Study

IRRAS AB (publ) to Report Q4, 2023 Results on Feb 21, 2024

IRRAS Receives US FDA 510(K) Clearance for Its Next Generation IRRAflow Control Unit

Is IRRAS (STO:IRRAS) In A Good Position To Deliver On Growth Plans?

IRRAS AB (publ) SHARE AK to Be Deleted from OTC Equity

Price target increased to kr5.00

Insufficient new directors

IRRAS AB (publ) to Report Q4, 2022 Results on Feb 22, 2023

IRRAS AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 214.599618 million.

Irras Announces First Patient Treatments At Mount Sinai Health System in New York as Part of the Dive Study

Second quarter 2022 earnings released: kr0.46 loss per share (vs kr0.40 loss in 2Q 2021)

IRRAS AB Provides Revenue Guidance for the Year 2022

Insufficient new directors

Price target decreased to kr7.00

IRRAS AB (publ) Announces First Global Patient Treatment with Next-Generation IRRAflow® System

IRRAS AB (publ) Launches Next-Generation of the IRRAflow System in the United States

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

IRRAS AB (publ) to Report Q2, 2022 Results on Jul 22, 2022

Consensus revenue estimates fall by 32%

IRRAS Announces Presentation of the Dataset to Date to Document Clinical Outcomes Using Its IRRAflow system

IRRAS Announces First Patients Enrolled in ACTIVE Study, a Comparative Clinical Trial Designed to Confirm IRRAflow's Efficacy to Traditional Passive Drainage

Here's Why We're A Bit Worried About IRRAS' (STO:IRRAS) Cash Burn Situation

Third quarter 2021 earnings released: kr0.34 loss per share (vs kr0.47 loss in 3Q 2020)

IRRAS AB (publ) Demonstrates Ability to Treat Pyogenic Ventriculitis Through Targeted Delivery of Antibiotics in Case Series Published in Neurosurgery Open

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.55 loss in 2Q 2020)

IRRAS AB Receives Extension of Its MDSAP Certification and Scope Expansion of MDSAP & ISO 13485:2016 Certifications

IRRAS AB Announces Publication of A Case Report from Buffalo General Medical Center, Highlights Clinical Superiority of IRRAflow Treatment Versus Traditional Drainage

Price target decreased to kr8.70

First quarter 2021 earnings released: kr0.58 loss per share (vs kr1.19 loss in 1Q 2020)

We Think IRRAS (STO:IRRAS) Needs To Drive Business Growth Carefully

Irras Announces the Recruitment of Sten Gustafsson as Director of Investor Relations

Analysts update estimates

Full year 2020 earnings released: kr24.64 loss per share (vs kr5.61 loss in FY 2019)

Price target lowered to kr10.25

Earnings beat expectations, revenue disappoints

New 90-day low: kr6.11

Price target lowered to kr11.00

Analysts update estimates

Irras AB Announces an Exclusive Distribution Agreement with Medical Innovation Solutions

IRRAS AB Announces Exclusive Distribution Agreement with Anade SA

New 90-day high: kr9.00

IRRAS AB Announces an Exclusive Distribution Agreement with KM Innovations BV

IRRAS AB Announces Breakthrough Technology Purchasing Agreement with Premier for Hummingbird ICP Monitoring Products

Third quarter 2020 earnings released: kr0.47 loss per share

Revenue and earnings miss expectations

Analysts lower revenue estimates to kr10.7m

Price target lowered to kr12.00

New 90-day high: kr6.98

Analysts increase revenue estimates to kr27.5m

First half earnings released

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta